Pharmaceuticals

Marking One Year Milestone, ADDI Expands Access to Global Data for Alzheimer's Researchers

Organization saw growth in AD Workbench users, data partners, and patient datasets from across the globe, including from low- and middle-income countries  SEATTLE, Nov. 17, 2021 /PRNewswire/ -- Today, the Alzheimer's Disease Data Initiative (ADDI) marked one year of transforming how Alzheimer's d...

2021-11-17 19:00 2183

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-11-17 18:52 3086

Inmagene files two international patent applications

SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company") announced that it has filed two international patent applications for its drug candidates, IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application...

2021-11-17 18:30 1379

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

SINGAPORE, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today announc...

2021-11-17 09:10 2066

Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine

TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burdens, recently announced that the c...

2021-11-17 09:00 2225

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

* The therapy aims to re-energize a patient's immune system to fight cancer tumors * Initial commercialization will target leading oncology centers in Germany, France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021 /PRNewswire/ --Terumo Blood and Cell Technologies

2021-11-17 00:00 1654

Kira Pharmaceuticals Appoints Teri Loxam as Chief Operating Officer and Chief Financial Officer

CAMBRIDGE, Mass. and SUZHOU, Jiangsu, China, Nov. 16, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, today announced the appointment ofTeri Loxam as Chief Operating Officer (COO...

2021-11-16 19:00 2037

Advanced Sterilization Products' Global Commercial Leader, Nilesh Shah, sets sights on preventing HAIs in Asia

SINGAPORE, Nov. 16, 2021 /PRNewswire/ -- Advanced Sterilization Products' (ASP) recently appointed Vice President, General Manager and Global Commercial Leader, Nilesh Shah looks to strengthen ASP's footing in growing markets to improve healthcare standards by reducing the rate of healthcare-assoc...

2021-11-16 10:05 4261

Baxter Philippines launches My Kidney Journey portal to support patients with Chronic Kidney Disease

MANILA, Philippines, Nov. 16, 2021 /PRNewswire/ -- Baxter Asia Pacific (Baxter), a global leader in dialysis care, announced today the launch ofMy Kidney Journey, a comprehensive online portal to support patients living with Chronic Kidney Disease (CKD) inthe Philippines. Chronic Kidney Disease ...

2021-11-16 10:00 1512

Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee

-- Inclusion in the "Best of The Liver Meeting's Summary" is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB -- In patients with the baseline HBsAg level ≤ 500 IU/mL, the Phase IIb study demonstrated sustained HBsAg loss in 19...

2021-11-16 08:35 2488

Nanoform signs GMP agreement and achieves near-term business target

HELSINKI, Nov. 15, 2021 /PRNewswire/ -- Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling ...

2021-11-15 23:17 1653

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved

BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...

2021-11-15 22:47 2257

Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium

TAIPEI and SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting clinical design for their lead drug candidate...

2021-11-15 20:00 1476

Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention

JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI

2021-11-15 20:00 1274

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...

2021-11-15 20:00 2698

Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing

SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....

2021-11-15 19:00 1605

Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...

2021-11-15 08:30 2418

Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-15 08:00 2580

Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...

2021-11-13 02:56 4401

Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China

SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...

2021-11-12 14:17 1730
1 ... 210211212213214215216 ... 314